Geographical Variation in Hospitalization for Psychosis Associated with Cannabis Use and Cannabis Legalization in the United States: Submit To: Psychiatry Research

Overview

Journal Psychiatry Res

Specialty Psychiatry

Date 2022 Jan 11

PMID 35016118

Authors

Lauren V Moran

Erica S Tsang

Dost Ongur

John Hsu

May Y Choi

Affiliations

Soon will be listed here.

Abstract

The 2017 National Inpatient Sample database was utilized to investigate the association between cannabis legalization in the United States and hospitalizations for psychosis associated with cannabis use. We compared the odds of hospital discharges for psychosis associated with cannabis use in adults between the Pacific census division (where most states legalized recreational cannabis use) and other divisions using multivariable logistic regression, adjusting for confounders. We calculated a score for each census division representing cannabis legality as the population-weighted sum of state scores: 1=illegal or cannabidiol/low potency cannabis; 2= medical marijuana; and 3=recreational and medical marijuana legalized. Pearson's correlation coefficients (r) quantified the relationship between scores and the proportion of hospitalizations with psychosis associated with cannabis. In 2017, there were an estimated 129,070 hospital discharges for psychosis associated with cannabis use. The Pacific census division had significantly higher odds of discharges than other divisions (adjusted odds ratio 1.55; 95% confidence interval 1.25 - 1.93). There was a significant correlation between the cannabis legality score and proportion of hospital discharges for psychosis associated with cannabis use (r = 0.67, p<0.05). In conclusion, we observed a higher proportion of hospital discharges for psychosis associated with cannabis use in areas with more liberal cannabis legalization laws.

Citing Articles

Cannabis Use Cessation and the Risk of Psychotic Disorders: A Case-Control Analysis from the First Episode Case-Control EU-GEI WP2 Study: L'arrêt de l'utilisation du cannabis et le risque de troubles psychotiques: Une analyse cas-témoins tirée de....

Bond B, Duric B, Spinazzola E, Trotta G, Chesney E, Li Z Can J Psychiatry. 2025; 70(3):182-193.

PMID: 39810593 PMC: 11733868. DOI: 10.1177/07067437241290187.

The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.

Austin-Zimmerman I, Spinazzola E, Quattrone D, Wu-Choi B, Trotta G, Li Z Psychol Med. 2024; :1-13.

PMID: 39637925 PMC: 11650186. DOI: 10.1017/S0033291724002058.

Acute Toxicity and Pharmacokinetic Profile of an EU-GMP-Certified L. in Rodents.

Filipiuc L, Stefanescu R, Solcan C, Ciorpac M, Szilagyi A, Cojocaru D Pharmaceuticals (Basel). 2023; 16(5).

PMID: 37242477 PMC: 10223347. DOI: 10.3390/ph16050694.

State Cannabis Legalization and Psychosis-Related Health Care Utilization.

Elser H, Humphreys K, Kiang M, Mehta S, Yoon J, Faustman W JAMA Netw Open. 2023; 6(1):e2252689.

PMID: 36696111 PMC: 9925044. DOI: 10.1001/jamanetworkopen.2022.52689.

References

van Os J, Bak M, Hanssen M, Bijl R, de Graaf R, Verdoux H . Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002; 156(4):319-27. DOI: 10.1093/aje/kwf043. View

Marconi A, Di Forti M, Lewis C, Murray R, Vassos E . Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophr Bull. 2016; 42(5):1262-9. PMC: 4988731. DOI: 10.1093/schbul/sbw003. View

Compton W, Han B, Jones C, Blanco C, Hughes A . Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys. Lancet Psychiatry. 2016; 3(10):954-964. DOI: 10.1016/S2215-0366(16)30208-5. View

Andreasson S, Allebeck P, Engstrom A, Rydberg U . Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987; 2(8574):1483-6. DOI: 10.1016/s0140-6736(87)92620-1. View

Hesketh P, Kris M, Basch E, Bohlke K, Barbour S, Clark-Snow R . Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(28):3240-3261. DOI: 10.1200/JCO.2017.74.4789. View

Davis J, Mendelson B, Berkes J, Suleta K, Corsi K, Booth R . Public Health Effects of Medical Marijuana Legalization in Colorado. Am J Prev Med. 2015; 50(3):373-379. PMC: 4762755. DOI: 10.1016/j.amepre.2015.06.034. View

Claflin S, van der Mei I, Taylor B . Complementary and alternative treatments of multiple sclerosis: a review of the evidence from 2001 to 2016. J Neurol Neurosurg Psychiatry. 2017; 89(1):34-41. DOI: 10.1136/jnnp-2016-314490. View

Zajicek J, Hobart J, Slade A, Barnes D, Mattison P . Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012; 83(11):1125-32. DOI: 10.1136/jnnp-2012-302468. View

Van Dijk D, Koeter M, Hijman R, Kahn R, van den Brink W . Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizophr Res. 2012; 137(1-3):50-7. DOI: 10.1016/j.schres.2012.01.016. View

10.

Hasin D . US Epidemiology of Cannabis Use and Associated Problems. Neuropsychopharmacology. 2017; 43(1):195-212. PMC: 5719106. DOI: 10.1038/npp.2017.198. View

11.

Phillips T, Cherry C, Cox S, Marshall S, Rice A . Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2011; 5(12):e14433. PMC: 3010990. DOI: 10.1371/journal.pone.0014433. View

12.

Johal H, Devji T, Chang Y, Simone J, Vannabouathong C, Bhandari M . Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis. Clin Med Insights Arthritis Musculoskelet Disord. 2020; 13:1179544120906461. PMC: 7031792. DOI: 10.1177/1179544120906461. View

13.

DSouza D, Perry E, Macdougall L, Ammerman Y, Cooper T, Wu Y . The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004; 29(8):1558-72. DOI: 10.1038/sj.npp.1300496. View

14.

Di Forti M, Quattrone D, Freeman T, Tripoli G, Gayer-Anderson C, Quigley H . The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019; 6(5):427-436. PMC: 7646282. DOI: 10.1016/S2215-0366(19)30048-3. View

15.

Chong S, Subramaniam M, Lee I, Pek E, Cheok C, Verma S . Academic attainment: a predictor of psychiatric disorders?. Soc Psychiatry Psychiatr Epidemiol. 2009; 44(11):999-1004. DOI: 10.1007/s00127-009-0027-3. View

16.

Sarvet A, Wall M, Fink D, Greene E, Le A, Boustead A . Medical marijuana laws and adolescent marijuana use in the United States: a systematic review and meta-analysis. Addiction. 2018; 113(6):1003-1016. PMC: 5942879. DOI: 10.1111/add.14136. View

17.

Folsom D, Jeste D . Schizophrenia in homeless persons: a systematic review of the literature. Acta Psychiatr Scand. 2002; 105(6):404-13. DOI: 10.1034/j.1600-0447.2002.02209.x. View

18.

Loberg E, Helle S, Nygard M, Berle J, Kroken R, Johnsen E . The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability. Front Psychiatry. 2014; 5:159. PMC: 4235385. DOI: 10.3389/fpsyt.2014.00159. View

19.

Folsom D, Hawthorne W, Lindamer L, Gilmer T, Bailey A, Golshan S . Prevalence and risk factors for homelessness and utilization of mental health services among 10,340 patients with serious mental illness in a large public mental health system. Am J Psychiatry. 2005; 162(2):370-6. DOI: 10.1176/appi.ajp.162.2.370. View

20.

Palmer B, Pankratz V, Bostwick J . The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005; 62(3):247-53. DOI: 10.1001/archpsyc.62.3.247. View